Phagemid Vector
AssigneeImperial Innovations Limited
InventorsAmin Hajitou, Paladd Asavarut, Teerapong Yata
Life of this patent
Estimating the term…
Loading patent…
AssigneeImperial Innovations Limited
InventorsAmin Hajitou, Paladd Asavarut, Teerapong Yata
Estimating the term…
The invention provides hybrid and recombinant phagemid vectors for expressing a transgene in a target cell transduced with the vector. A recombinant phagemid particle comprises at least one transgene expression cassette which encodes an agent which exerts a biological effect on the target cell, characterised in that the phagemid particle comprises a genome which lacks at least 50% of its bacteriophage genome. The invention extends to the use of such phagemid expression systems as a research tool, and for the delivery of transgenes in a variety of gene therapy applications, DNA and/or peptide vaccine delivery and imaging techniques. The invention extends to in vitro, in vivo or in situ methods for producing viral vectors, such as recombinant adeno-associated viruses (rAAV) or lentivirus vectors (rLV), and to genetic constructs used in such methods.
A recombinant phagemid particle for expressing a transgene in a target cell transduced with the particle, the phagemid particle comprising at least one transgene expression cassette which encodes an agent which exerts a biological effect on the target cell, characterised in that the phagemid particle comprises a genome which lacks at least 50% of its bacteriophage genome.
A particle according to any preceding claim, wherein the genome of the recombinant phagemid particle comprises an origin of replication for enabling replication of double-stranded vector inside a prokaryotic host, optionally a pUC ori.
A particle according to any preceding claim, wherein the genome of the recombinant phagemid particle comprises one or more DNA sequence, which favours targeted integration into a host genome.
A particle according to any preceding claim, wherein the at least one transgene expression cassette comprises a viral transgene expression cassette.
A particle according to any preceding claim, wherein the at least one transgene expression cassette comprises a mammalian viral transgene expression cassette.
A particle according to any preceding claim, wherein the at least one transgene expression cassette comprises a lentivirus transgene expression cassette.
A particle according to any preceding claim, wherein the at least one transgene expression cassette comprises an adeno-associated virus (AAV) transgene expression cassette.
A particle according to any preceding claim, wherein the transgene expression cassette comprises a nucleic acid encoding an agent, which has therapeutic or industrial utility in the target cell or tissue.
A particle according to any preceding claim, wherein the transgene expression cassette comprises one or more functional elements required for expression of the nucleic acid in the target cell selected from the groups consisting of:
A particle according to any preceding claim, wherein the recombinant phagemid particle comprises one or more capsid minor coat protein, optionally wherein the recombinant phagemid particle comprises a pIII capsid minor coat protein that is configured to display a cell-targeting ligand for enabling delivery of the particle to the target cell.
A particle according to any preceding claim, wherein the recombinant phagemid particle comprises one or more capsid major coat protein, optionally wherein the recombinant phagemid particle comprises at least one pVIII capsid major coat protein that is configured to display a foreign peptide thereon.
A particle according to any preceding claim, wherein the recombinant phagemid particle is combined with a cationic polymer to form a complex having a net positive charge, optionally wherein the cationic polymer is selected from a group consisting of:
A particle according to any preceding claim, wherein the genome of the recombinant phagemid particle lacks at least 60%, 70%, or at least 80% of the bacteriophage genome from which it is derived.
A particle according to any preceding claim, wherein the genome of the recombinant phagemid particle lacks at least 90%, 95%, or at least 99% of the bacteriophage genome from which it is derived.
A particle according to any preceding claim, wherein the phagemid particle lacks bacteriophage structural genes in its genome required for the formation, packaging or extrusion of the particle from a prokaryotic host, preferably structural genes which encode the capsid proteins.
A system for producing a recombinant phagemid particle from a prokaryotic host, the system comprising:
A method for producing a recombinant phagemid particle from a prokaryotic host, the method comprising:
A method for producing a recombinant phagemid particle from a prokaryotic host, the method comprising:
A recombinant vector comprising comprising rAAV, rep-cap and adenohelper genes.
Dependencies are inferred from the claim text.